EMPATHY: Patient-reported outcomes clustered RCT


Project leads: Dr. Jeffrey Johnson and Dr. Michael Walsh Regions: Alberta and Ontario The prevalence of chronic kidney disease (CKD) is increasing in Canada with prevalence rates reaching up to 12.5% (3 million Canadian adults), and 3.1% (0.73 million adults) for stages 3-5. Advanced CKD requiring dialysis is expensive and is associated with poor health outcomes [...]

Evaluation of sodium deposition in soft tissues of patients with kidney disease and its association with patient symptomatology


Project lead: Dr. Chris McIntyre One key function of the kidney is to balance the level of sodium in our bodies by getting rid of it through urine. There have been studies that show when kidney function is impaired, the extra sodium may end up on skin, muscle or bones, causing inflammation. There is a potential [...]

DISCO: Dialysis Symptom Control


Project lead: Dr. Michael Walsh Patient lead: Gwen Herrington Patients being treated with dialysis for end-stage kidney disease frequently suffer from symptoms like itchiness and restless legs. Despite how common these symptoms are, there is very little evidence about what the best treatments are. The DISCO Trials will explore whether promising treatments, some of which are already [...]

ACHIEVE: Aldosterone inhibition and enhanced toxin removal in hemodialysis patients


Project lead: Dr. Michael Walsh and Dr. David Collister Patient Group: Patients who are or were on dialysis Region: All regions Forty percent of patients that require dialysis die within three years, mostly due to heart disease. Spironolactone is a drug that is very effective at reducing scarring of the heart and might help prevent heart-related deaths in [...]

Clinical trials of promising re-purposed drugs for ADPKD


Project lead: Dr. York Pei Patient lead: David Hillier Patient group: Adult patients with polycystic kidney disease without end-stage renal disease Region: All regions View Project Website Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease. There are two types of ADPKD due to mutations of two different genes: PKD1 and PKD2. PKD1 is generally [...]

Cell therapy interventions to prevent loss of kidney function


Project leads: Dr. Richard Gilbert and Dr. Kevin Burns Patient lead: Gwen Herrington Patient group: Older (Indigenous and non-Indigenous) patients with diabetes Region: All regions Diabetes is the most common cause of end-stage kidney failure in Canada. The main cause of reduced kidney function in diabetes is the slow loss of small blood vessels (capillaries) combined with scar tissue (fibrosis). [...]